Company news

InMed Pharmaceuticals Inc. news in 2024

InMed Pharmaceuticals Inc.'s news releases, calls and decks from 2024, newest first.

View company

InMed Announces Results of 2024 Annual General Meeting

December 17, 2024

InMed Enters Into Standby Equity Purchase Agreement

December 16, 2024

InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System

November 18, 2024

InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

November 13, 2024

InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules

November 7, 2024

InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules

November 4, 2024

InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease

October 27, 2024

InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease

October 23, 2024

InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board

October 21, 2024

InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update

September 29, 2024

InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date

September 19, 2024

InMed Demonstrates Encouraging Data For Its Cannabinoid INM-089 In Treating Dry AMD, An Ocular Disease With Rising Patient Numbers As National Population Ages

August 27, 2024

InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents

August 20, 2024

InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease

August 19, 2024

InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data

July 29, 2024

InMed to Present at the Emerging Growth Conference

June 9, 2024

InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

May 13, 2024

InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board

April 17, 2024

InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration

April 15, 2024

InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies

April 3, 2024

InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

March 19, 2024

InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update

February 12, 2024

InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer

February 8, 2024

InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET

January 17, 2024

InMed Pharmaceuticals Provides Business Update and Milestones for 2024

January 15, 2024

Decks in 2024